Lung Cancer Europe shared a post on X about a recent article by Mariano Provencio et al, published in Nature Communications:
“Another interesting study to end ’25 – a Spanish phase 2 trial explored starting immunotherapy before chemoradiotherapy in unresectable stage 3 Lung Cancer.
The discussion it’s sparked is important too. It reflects a shift in thinking, away from fixed labels and single treatment pathways, towards starting systemic treatment earlier and then deciding together what local treatment, if any, makes sense.”
Title: Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial
Authors: Mariano Provencio, Begoña Campos, María Guirado, Laia Vila, Rosario García Campelo, Miriam Dorta, Sergio Vázquez Estévez, Asia Ferrández, M. Ángeles Sala, Ana Laura Ortega, Ana Blasco, Jessica Sullivan, Manuel Fernández Bruno, Cristina Martínez-Toledo, Pilar Mediavilla, Emilio Sánchez Saugar, Laura Torrado, John K. Matskov, Atocha Romero, Alberto Cruz-Bermúdez
Read the full article on Nature Communications.
More posts featuring Lung Cancer Europe on OncoDaily.